Omeros Financial Results
Omeros Corporation reported Q3 2026 financial results, highlighted by a 26% sequential increase in net revenue for YARTEMLEA to $35.9 million. The company reported a GAAP net loss of $57.4 million, primarily driven by a $62.0 million non-cash mark-to-market adjustment on convertible notes, while achieving positive operating cash flow of $13.3 million.
- Term
- Q3 2026
“YARTEMLEA sales continued to grow during the third quarter, delivering consecutive quarters of positive operating cash flow. As expected, 340B participation increased, reflecting substantial expansion of our customer base and increased outpatient use of YARTEMLEA. That momentum has continued into the fourth quarter, with YARTEMLEA revenues continuing to grow.”
Gregory A. Demopulos, M.D., Omeros’ Chairman and Chief Executive Officer